Navigation Links
AnaptysBio Announces New Strategic Antibody Discovery
Date:1/6/2012

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.    The strategic alliance announced today with Novartis is AnaptysBio's second collaboration with the Swiss-based pharmaceutical company and follows an initial partnership where AnaptysBio successfully delivered antibody candidates for Novartis' development pipeline. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

Under the terms of each alliance, AnaptysBio will utilize its proprietary SHM-XEL platform for the discovery and maturation of novel therapeutic antibodies to multiple oncology-related therapeutic targets.  Each pharmaceutical partner will receive worldwide rights to develop and commercialize a limited number of antibodies against each therapeutic target generated by AnaptysBio.   In addition to an upfront payment and resource-based compensation, AnaptysBio is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from these alliances.

AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.  The use of mammalian cell display permits AnaptysBio to optimize manufacturing-related parameters by selecting for high-level expression and stability in parallel.  Simultaneous secretion of antibody variants by the mammalian cells utilized during SHM-XEL also permits incorporation of functional assays in the antibody discovery process.   Key hallmarks of the SHM-XEL platform were recently published by AnaptysBio in Proceedings of the National Academy of Sciences (PNAS (2011), 108, 20455-20460).

"Our technology platform provides an integrated approach to antibody discovery using the natural biochemistry of somatic hypermutation in the context of mammalian cells," said Hamza Suria, president and chief executive officer for AnaptysBio. "We will continue to generate differentiated therapeutic candidates for our internal pipeline and under strategic alliances with select pharmaceutical partners."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies. The Company's SHM-XEL platform couples SHM with mammalian cell display to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection under controlled conditions – a process that has been referred to as "naturalizing" antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired properties for therapeutic applications. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit www.anaptysbio.com.

Contacts:

Julie Rathbun

julie@rathbuncomm.com

206-769-9219


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. AtheroNova Announces a New Board Member
4. RSB Spine, LLC Announces 2011 Revenue Growth
5. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
6. Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
7. Verify Brand™ Announces the Release of VB Enterprise 4.0
8. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
9. NeoStem Announces Participation in Multiple January Conferences
10. Bionovo Announces $5 Million Financing
11. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... being developed with Wi-Fi connectivity to reduce the amount of wiring in a ... In addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cloud-based file transfer solution that makes it easy for organizations to send and ... worry about cumbersome FTP software or email file size limitations. , Using ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions ... in the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research defines ... market demand, and effectively perform against those strategies. NetDimensions’ ranking as a Leader ...
Breaking Biology Technology:
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):